Skip to main content

ACR 2019 - Report from Day One (Sunday)

Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one. 

Delays in Diagnosis

Updates on Psoriatic Arthritis at ACR 2018

Memorable annual conferences are usually marked by a key focus on an emerging area of interest. I think 2018 was the year that belonged to psoriatic arthritis (although some may argue in favour of immune conditions induced by Checkpoint inhibitors).

Test on New ACR19 Site

Body text

Updates on Psoriatic Arthritis at ACR 2018

Memorable annual conferences are usually marked by a key focus on an emerging area of interest. I think 2018 was the year that belonged to psoriatic arthritis (although some may argue in favour of immune conditions induced by Checkpoint inhibitors).

Tweets

Dr. John Cush RheumNow

8 months ago

#ACR19 Rheumatology RoundUp - Kavanaughs Picks: 2505 PsA prevention 1366 Self Joint exams 1120 Rheum burnout 1310 OA Hx 565 Enteropathic arthritis Recs 1823 MRE dx of SI 2773 Machine learning 2772 Antiinflammatory diet in RA 1359 Synovial Bx

Janet Pope Janetbirdope

8 months ago

Killed zoster vaccine was safe with no flare of RA and PsA We need to know if response was good. #ACR19 @RheumNow abst2093 https://t.co/xp2Ju5wZWK

Janet Pope Janetbirdope

8 months ago

1/3 of pts using apremilast with PsA/SpA from Corrona data base are using it in combination with bDMARDs. Not sure how they get reimbursement #ACR #ACR19 #psoriaticarthritis @RheumNow abstract 1481

Dr. Rachel Tate uptoTate

8 months ago

MAXIMISE results in axial manifestations of PsA. SEC met primary phase 3b ASAS 20 endpoint after inadequate NSAID response. https://t.co/e1j03KOo1K #ACR19 @RheumNow abs#2880 https://t.co/UtSDJGAW2G

Dr. Rachel Tate uptoTate

8 months ago

Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/uHvkFJn5z7 #ACR19 @RheumNow abs#2881 https://t.co/2EfzmyxY4M

Dr. Rachel Tate uptoTate

8 months ago

Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase 2 results. No new safety signals noted. https://t.co/Jv1zpcg5Zd #ACR19 @RheumNow abs#2877

Janet Pope Janetbirdope

8 months ago

Tofa is not different from bDMARDs in Corrona for cancer and deaths. reassuring and adds to growing safety data #ACR #ACR19 @RheumNow abstr 2874 https://t.co/pLVAkQ7UR6

Dr. Rachel Tate uptoTate

8 months ago

Go-DACT proof on concept results: golimumab + MTX superior to monotherapy MTX in PsA dactylitis. https://t.co/dEGnjiuGZf #ACR19 @RheumNow abs#2876

Mike Putman EBRheum

8 months ago

#ACR19 Abst#2877: Open Label Extension of a Phase 2 for risankizumab (IL23i) for PsA Effect seems to stick around and favorable safety profile @RheumNow https://t.co/pFn0q61exs

Mike Putman EBRheum

8 months ago

Great talk by Dr. Manzi for Year in Review! See my recent podcast about SPIRIT-H2H. It shows that IXE > ADA for skin but NOT for joints. @RheumNow #ACR19 https://t.co/FzY8O7KX1A

×